Nathalie BALANDRAUD – MD and PhD

• 1984-1991 – Medical school, University Lyon-Nord , France
• 1991 – Internship
• 1998 – Specialization in Rheumatology
• 1999 – MD Medical Doctor , Medical school Lyon, France

• 1993 – MASTER degree in fundamental and experimental pharmaco-kinetic and drug effect on humans, Aix Marseille University.
• 2003 – PhD in Osteoarticular Biology, Denis Diderot, Université de Paris.
• 2005-2006 –  Post doctoral position, In P Pontarotti’s group, EGGE Genome, Environment, Evolution , Aix Marseille University.
• 2017 – French university degree to supervise PhD students (HDR), Toulouse Paul Sabatier University.

I am a consulting doctor in a Rheumatology ward (Hospital Practitioner), taking care of patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis.

I am also a researcher in the «Autoimmune Arthritis» group at INSERM UMRS1097, Aix Marseille university.

The lab studies the mechanisms leading to autoimmunity in arthritis. My focus is genetic background, LT activation after PAD 4 immunization. We also work on auto antibodies in Psoriatic arthritis.

Larid G, Pancarte M, Offer G, Clavel C, Martin M, Pradel V, Auger I, Lafforgue P, Roudier J, Serre G, Balandraud N.  In Rheumatoid Arthritis Patients, HLA-DRB1*04:01 and Rheumatoid Nodules Are Associated With ACPA to a Particular Fibrin Epitope. Front Immunol. 2021 Jun 24;12:692041. doi: 10.3389/fimmu.2021.692041. eCollection 2021.PMID: 34248985 

Perrot L, Hemon M, Busnel JM, Muis-Pistor O, Picard C, Zandotti C, Pham T, Roudier J, Desplat-Jego S, Balandraud N. First flare of ACPA-positive rheumatoid arthritis after SARS-CoV-2 infection. Lancet Rheumatol. 2021 Jan;3(1):e6-e8. doi: 10.1016/S2665-9913(20)30396-9. Epub 2020 Nov 23.PMID: 33521668 

Balandraud N.* and Auger I.*, Roudier J. Do RA associated HLA-DR molecules bind citrullinated peptides or peptides from PAD4 to help the development of RA specific antibodies to citrullinated proteins? J Autoimmun. 2021 Jan;116:102542. doi: 10.1016/j.jaut.2020.102542. Epub 2020 Sep 11.PMID: 32928608 

Auger I* and Balandraud N*, Massy E, Hemon MF, Peen E, Arnoux F, Mariot C, Martin M, Lafforgue P, Busnel JM, Roudier J. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model. Arthritis Rheumatol. 2020 Jun;72(6):903-911. doi: 10.1002/art.41189. Epub 2020 Apr 26.PMID: 31820586

Balandraud N, Gaetan Texier, Emmanuel Massy, Olivier Muis-Pistor, Marielle Martin, Isabelle Auger, Marie-Caroline Guzian, Jean-Pierre Mattei, Sandrine Guis, Thao Pham, Jean Roudier. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis, a three years prospective study in France , PLOS ONE 2017 Feb 15;12(2):e0171623. doi: 10.1371/journal.pone.0171623. PMID: 28199343

Montoya J, Matta NB, Suchon P, Guzian MC, Lambert NC, Mattei JP, Guis S, Breban M, Roudier J, Balandraud N. Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study. Ann Rheum Dis. 2015 doi: 10.1136/annrheumdis-2015-208187.

Silvy F, Bertin D, Bardin N, Auger I, Guzian MC, Mattei JP, Guis S, Roudier J, Balandraud N. Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics. PLoS One. 2015 Jul 31;10(7):e0134218

Balandraud N, Picard C, Reviron D, Landais C, Toussirot E, Lambert N, Telle E, Charpin C, Wendling D, Pardoux E, Auger I, Roudier J. HLA-DRB1 genotypes and the risk of developing anti citrullinated protein antibody (ACPA) positive rheumatoid arthritis. PLoS One. 2013 May 30;8(5):e64108. doi: 10.1371/journal.pone.0064108.

Auger I, Balandraud N, Rak J, Lambert N, Martin M, Roudier J. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis. 2009 Apr;68(4):591-4. doi: 10.1136/ard.2008.096917.

Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-barr virus load in patients with rheumatoid arthritis. Arthritis and Rheumatism 2007 Jun 15;57(5):762-7. doi: 10.1002/art.22783.